Skip to main content

Table 5 Prognostic factors for DFS and OS by univariate analysis

From: The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma

Variables n DFS P OS P
1-yr 3-yrs 5-yrs 1-yr 3-yrs 5-yrs
Sex          
Male 68 54.4% 36.8% 30.7% 0.53 79.4% 50.0% 41.2% 0.48
Female 16 56.3% 37.5% 37.5% 87.5% 56.3% 50.0%
Age(yrs)          
 <60 68 45.6% 32.4% 29.3% 0.15 82.4% 48.5% 39.7% 0.39
 ≥60 16 62.5% 56.3% 42.2% 75.0% 62.5% 56.3%
HCC family history          
 Yes 6 50.0% 33.3% 16.7% 0.57 83.3% 50.0% 50.0% 0.63
 No 78 48.7% 37.2% 33.3% 79.5% 51.3% 42.3%
PLT(×109)          
 <100 10 80.0% 60.0% 60.0% 0.07 100.0% 80.0% 70.0% 0.08
 ≥100 74 44.6% 33.8% 28.2% 78.4% 47.3% 39.2%
HBsAg          
 Positive 72 47.2% 38.9% 33.3% 0.90 79.2% 50.0% 44.4% 0.88
 Negative 12 58.3% 25.0% 25.0% 91.7% 58.3% 33.3%
AFP(μg/L)          
 <20 36 52.8% 38.9% 38.9% 0.34 83.3% 50.0% 44.4% 0.75
 ≥20 48 45.8% 35.4% 26.7% 79.2% 52.1% 41.7%
Ascites          
 No 68 52.9% 39.7% 34.1% 0.14 83.8% 51.5% 44.1% 0.55
 Yes 16 31.3% 25.0% 25.0% 68.8% 50.0% 37.5%
Cirrhosis          
 No 24 45.0% 35.0% 30.0% 0.78 95.0% 60.0% 45.0% 0.49
 Yes 60 50.0% 37.5% 32.9% 76.6% 48.4% 42.2%
Tumor number          
 Single 62 59.7% 43.5% 36.9% 0.003 85.5% 61.3% 51.6% <0.001
 Multiple 22 18.2% 18.2% 18.2% 68.2% 22.7% 18.2%
 PVTT          
 No 73 54.8% 41.1% 35.4% <0.001 87.7% 56.2% 47.9% <0.001
 Yes 11 9.1% 9.1% 9.1% 36.4% 18.2% 9.1%
 Tumor size (cm)          
 <5 34 64.7% 47.1% 39.2% 0.05 97.1% 67.6% 52.9% 0.04
 ≥5 50 38.0% 30.0% 28.0% 70.0% 40.0% 36.0%
Tumor encapsulation          
 None 20 30.0% 25.0% 15.0% 0.01 60.0% 45.0% 30.0% 0.08
 Complete 64 54.7% 40.6% 37.7% 87.5% 53.1% 46.9%
Resection margin          
 <2 cm 45 40.0% 26.7% 24.4% 0.07 80.0% 40.0% 28.9% 0.01
 ≥2 cm 39 59.0% 48.7% 39.6% 82.1% 64.1% 59.0%
Complication          
 No 73 49.3% 38.4% 33.1% 0.37 84.9% 53.4% 45.2% 0.10
 Yes 11 45.5% 27.3% 27.3% 54.5% 36.4% 27.3%
 Tumor differetiation          
 I-II 62 54.8% 41.9% 35.1% 0.16 85.5% 56.5% 48.4% 0.04
 III-IV 22 31.8% 22.7% 22.7% 68.2% 36.4% 27.3%
TNM stage          
 I-II 55 60.0% 43.6% 38.0% 0.01 90.9% 60% 52.7% 0.001
 III-IV 29 27.6% 24.1% 20.7% 62.1% 34.5% 24.1%
ELF expression          
 Low 44 25.0% 15.9% 10.2% <0.001 72.7% 31.8% 23.7% <0.001
 High 40 75.0% 60.0% 57.5% 90.0% 72.5% 65.0%
TGFβ1 expression          
 Low 34 79.4% 73.5% 62.0% <0.001 94.1% 85.3% 76.5% <0.001
 High 50 28.0% 12.0% 12.0% 72.0% 28.0% 20.0%
  1. AFP, Alpha-fetoprotein; HBsAg, hepatitis B surface antigen; PLT, platelet; PVTT, portal vein tumor thrombi.
\